Preview this article 1 min Harmony Biosciences also raised its overall 2025 revenue guidance. The State of Biotech Industry: ...

Ventyx Biosciences, Inc. surged after strong Phase 2 results for VTX3232 in obesity. Click for key insights and what VTYX ...

A biology teacher has become the first patient in the UK to receive a "gamechanger" therapy to treat multiple sclerosis (MS).

The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Alligator Bioscience AB ( ($SE:ATORX) ) has issued an update. Alligator Bioscience AB reported significant progress in its clinical and financial ...

This 5-month study plan guides CBSE Class 12 students for the 2026 Biology Board Exam, with unit-wise weightage, focusing on ...

An international research team has determined the first high-resolution structures of the herpes simplex virus origin-binding ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the ...

As GLP-1 weight-loss drugs like Ozempic reshape how consumers eat, food and beverage manufacturers are racing to develop ...

A University of Alberta research team is shedding much-needed light on cancer cachexia, a severe muscle-wasting syndrome ...

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the firs ...

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.